search
Back to results

Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia

Primary Purpose

Pneumonia

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Oral amoxicillin
Sponsored by
Boston Medical Center
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Pneumonia focused on measuring Pneumonia

Eligibility Criteria

2 Months - 59 Months (Child)All Sexes

Inclusion Criteria: Children aged three to 59 months admitted with severe pneumonia. Severe pneumonia is defined as lower chest indrawing in children with cough and/or difficult breathing, who are able to drink and do not have central cyanosis, regardless of the respiratory rate. Known HIV infected patients in clinical category N or A (CDC) will be included. Exclusion Criteria: Presence of any danger sign during current illness (convulsions, abnormally sleepy or difficult to awake, stridor in a calm child). Severe malnutrition defined as weight for age equal or less than -3 SD or kwashiorkor). Hospitalization in the last two weeks. This will exclude cases with possible nosocomial pneumonia that could require second line antibiotics. Known prior episodes of asthma. These patients may have respiratory distress without infection and most often do not need antibiotics. Children having had 3 or more episodes of wheezing in the past will also be excluded. Wheezing that improves after receiving bronchodilator therapy, as explained in the footnote . These children may have asthma. Measles in the last month. These patients may have immune suppression. Previous history of HIV infection in clinical category B or C (CDC). These patients have immune suppression and infections that may require other diagnostic or treatment measures (see annex 1, page 39). Known or clinically recognizable chronic conditions (congenital cardiac or respiratory anomalies, chronic lung disease including bronchopulmonary dysplasia, neurological impairment that affects respiratory function, renal diseases, malignant or hematological diseases). Other diseases requiring antibiotic therapy on presenting, such as meningitis, evident tuberculosis, dysentery, osteomyelitis, septic arthritis, etc. Use of other antibiotics needed for treatment. Children Lower Chest Indrawing due to non-infective cause such cardiac failure, active rickets, or severe anemia, or with signs of severe dehydration according to WHO criteria (see annex 2, page 42). Children with SaO2 <80% in room air at sea level, or SaO2 < 75% in Bogota and Mexico (for measurement of oxygen saturation see Study Manual). Known prior anaphylactic reaction to penicillin or amoxycillin. Known antibiotic therapy for 48 hours or more prior to admission. Clinically, these children would be considered for a change of treatment to second line antibiotics on admission. Evidence of antibiotic use include any of the following: a) parental report that an antibiotics has been given; b) parent can provide evidence for prescription for antibiotics or c) has the container with antibiotic or d) recognizes medication when shown appropriate containers for locally available antibiotics. Children that have received antibiotics for less than 48 hours prior to admission will be accepted in the trial. Inability to receive oral medications (three or more episodes of vomiting per hour). These children should not be given oral antibiotics. Previous inclusion in the trial or children already included in another trial. Living outside the catchment area of the hospital. These patients may be difficult to follow after discharge. Parental or caretaker refusal to participate in the trial.

Sites / Locations

    Outcomes

    Primary Outcome Measures

    The primary outcome was treatment failure at 48 hours.

    Secondary Outcome Measures

    Secondary outcomes were treatment failure at five days and 14 days.

    Full Information

    First Posted
    September 26, 2005
    Last Updated
    May 2, 2006
    Sponsor
    Boston Medical Center
    Collaborators
    World Health Organization
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00227331
    Brief Title
    Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia
    Official Title
    A Randomized Multicentre Equivalency Study Of Oral Amoxicillin Versus Injectable Penicillin In Children Aged 3 To 59 Months With Severe Pneumonia
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    September 2005
    Overall Recruitment Status
    Completed
    Study Start Date
    January 1998 (undefined)
    Primary Completion Date
    undefined (undefined)
    Study Completion Date
    January 2000 (undefined)

    3. Sponsor/Collaborators

    Name of the Sponsor
    Boston Medical Center
    Collaborators
    World Health Organization

    4. Oversight

    5. Study Description

    Brief Summary
    This is a clinical trial to determine if oral amoxicillin is equivalent in efficacy to injectable penicillin (the standard treatment) in the treatment of WHO-defined severe pneumonia in children between the ages of 2 and 59 months.
    Detailed Description
    BACKGROUND Injectable penicillin is recommended treatment for WHO-defined severe pneumonia (lower chest indrawing [LCI]). Oral amoxicillin, if found equally effective, could reduce referral, hospitalization, and treatment costs. We aimed to determine whether oral amoxicillin and parenteral penicillin were equivalent in the treatment of severe pneumonia in children aged 3-59 months. METHODS This multicentre randomized, open label equivalency study was conducted at tertiary care centres in 8 countries. Children aged 3-59 months with severe pneumonia were hospitalized for 48 hours and, if improved, discharged with a 5-day course of oral amoxicillin. Follow-up evaluation occurred at 5 and 14 days after enrolment. The primary outcome was treatment failure (persistence of LCI or new danger signs) at 48 hours. Analyses were by intention to treat and per protocol. RESULTS 1702 children were randomized to receive either oral amoxicillin (857) or parenteral penicillin (845) for 48 hours. Treatment failure was 19% in each group (risk difference -0.4; 95% CI -4.2 to 3.3) at 48 hours, 22% (cumulative) in each group at 5 days, and 25% in each group at 14 days. Relapse at day 5 and 14 occurred in 45/1375 (3.4%) and 65/1330 (4.8%) of the children, respectively. Infancy (OR 2.72, 95% CI 1.95-3.79), very fast breathing (1.94, 1.42-2.65) and hypoxia (1.95, 1.34-2.82) at baseline predicted treatment failure by multivariate analysis. CONCLUSIONS Injectable penicillin and oral amoxicillin are equivalent in the treatment of severe pneumonia in developing world areas in a controlled environment. Additional research is needed in a public health setting in rural and urban areas before these finding can be recommended for widespread implementation. Potential benefits of oral therapy for pneumonia include a decrease in the 1) the risk of needle-borne infections; 2) need for referral or hospitalization; 3) administration costs and 4) costs to the family. (word count 294).

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Pneumonia
    Keywords
    Pneumonia

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized

    8. Arms, Groups, and Interventions

    Intervention Type
    Drug
    Intervention Name(s)
    Oral amoxicillin
    Primary Outcome Measure Information:
    Title
    The primary outcome was treatment failure at 48 hours.
    Secondary Outcome Measure Information:
    Title
    Secondary outcomes were treatment failure at five days and 14 days.

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    2 Months
    Maximum Age & Unit of Time
    59 Months
    Eligibility Criteria
    Inclusion Criteria: Children aged three to 59 months admitted with severe pneumonia. Severe pneumonia is defined as lower chest indrawing in children with cough and/or difficult breathing, who are able to drink and do not have central cyanosis, regardless of the respiratory rate. Known HIV infected patients in clinical category N or A (CDC) will be included. Exclusion Criteria: Presence of any danger sign during current illness (convulsions, abnormally sleepy or difficult to awake, stridor in a calm child). Severe malnutrition defined as weight for age equal or less than -3 SD or kwashiorkor). Hospitalization in the last two weeks. This will exclude cases with possible nosocomial pneumonia that could require second line antibiotics. Known prior episodes of asthma. These patients may have respiratory distress without infection and most often do not need antibiotics. Children having had 3 or more episodes of wheezing in the past will also be excluded. Wheezing that improves after receiving bronchodilator therapy, as explained in the footnote . These children may have asthma. Measles in the last month. These patients may have immune suppression. Previous history of HIV infection in clinical category B or C (CDC). These patients have immune suppression and infections that may require other diagnostic or treatment measures (see annex 1, page 39). Known or clinically recognizable chronic conditions (congenital cardiac or respiratory anomalies, chronic lung disease including bronchopulmonary dysplasia, neurological impairment that affects respiratory function, renal diseases, malignant or hematological diseases). Other diseases requiring antibiotic therapy on presenting, such as meningitis, evident tuberculosis, dysentery, osteomyelitis, septic arthritis, etc. Use of other antibiotics needed for treatment. Children Lower Chest Indrawing due to non-infective cause such cardiac failure, active rickets, or severe anemia, or with signs of severe dehydration according to WHO criteria (see annex 2, page 42). Children with SaO2 <80% in room air at sea level, or SaO2 < 75% in Bogota and Mexico (for measurement of oxygen saturation see Study Manual). Known prior anaphylactic reaction to penicillin or amoxycillin. Known antibiotic therapy for 48 hours or more prior to admission. Clinically, these children would be considered for a change of treatment to second line antibiotics on admission. Evidence of antibiotic use include any of the following: a) parental report that an antibiotics has been given; b) parent can provide evidence for prescription for antibiotics or c) has the container with antibiotic or d) recognizes medication when shown appropriate containers for locally available antibiotics. Children that have received antibiotics for less than 48 hours prior to admission will be accepted in the trial. Inability to receive oral medications (three or more episodes of vomiting per hour). These children should not be given oral antibiotics. Previous inclusion in the trial or children already included in another trial. Living outside the catchment area of the hospital. These patients may be difficult to follow after discharge. Parental or caretaker refusal to participate in the trial.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Shamim Qazi, MD
    Organizational Affiliation
    World Health Organization
    Official's Role
    Study Chair

    12. IPD Sharing Statement

    Citations:
    PubMed Identifier
    16628299
    Citation
    Jeena P, Thea DM, MacLeod WB, Chisaka N, Fox MP, Coovadia HM, Qazi S; Amoxicillin Penicillin Pneumonia International Study (APPIS Group). Failure of standard antimicrobial therapy in children aged 3-59 months with mild or asymptomatic HIV infection and severe pneumonia. Bull World Health Organ. 2006 Apr;84(4):269-75. doi: 10.2471/blt.04.015222. Epub 2006 Apr 13.
    Results Reference
    result

    Learn more about this trial

    Equivalency Of Oral Amoxicillin Vs Injectable Penicillin In Children With Severe Pneumonia

    We'll reach out to this number within 24 hrs